TRONTIER study:Evaluating trontinemab for early Alzheimer's disease treatment
The TRONTIER study is a phase 3 clinical trial conducted by Roche to test a new drug, trontinemab, in people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. This treatment is experimental and not yet FDA-approved.
Study highlights
Key information about the TRONTIER study
- 50 to 85 years old
- Early Alzheimer's Disease
- Study partner (friend or family) available
- Infusion
- Study zone: Southern California + central Florida
Study goal and design
Phase 3 study targeting amyloid-beta in early Alzheimer's
The TRONTIER study is a Phase 3 clinical trial conducted by Roche, testing a new drug called Trontinemab in people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. The study checks if it's safe and if it can help by removing harmful amyloid-beta protein from the brain using a special technology to get the drug into the brain more effectively.
Study-related care and support
Comprehensive medical oversight and support
While contributing to research, participants receive:
- The possibility to receive trontinemab investigational study medication
- Regular brain scans and memory assessments
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journey
A structured research experience
Express your interest
Answer a questionnaire to check preliminary criteria.
Meet the study team
Complete a detailed brain and memory evaluation.
Begin treatment (or placebo)
Receive trontinemab or placebo by intravenous infusion. Participation duration is 72 weeks.
Continue the study
Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Ready to get involved?Join the TRONTIER study.
Contribute to progress, support research, help others, and care for your health.